AA
MLYS icon

ALPS Advisors’s Mineralys Therapeutics MLYS Stock Holding History

ALPS Advisors’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.75M Sell
64,419
-568
-0.9% -$16.7K 0.01% 432
2025
Q4 		$2.36M Buy
+64,987
New +$2.61M 0.01% 372
2025
Q2 		– Sell
-34,664
Closed -$550K – 1047
2025
Q1 		$550K Sell
34,664
-5,584
-14% -$64.2K ﹤0.01% 577
2024
Q4 		$495K Buy
40,248
+1,984
+5% +$25.9K ﹤0.01% 606
2024
Q3 		$463K Sell
38,264
-471
-1% -$5.7K ﹤0.01% 621
2024
Q2 		$453K Buy
38,735
+9,746
+34% +$123K ﹤0.01% 598
2024
Q1 		$374K Buy
28,989
+2,314
+9% +$28.6K ﹤0.01% 691
2023
Q4 		$229K Sell
26,675
-3,473
-12% -$27.3K ﹤0.01% 938
2023
Q3 		$287K Buy
30,148
+117
+0.4% +$1.53K ﹤0.01% 896
2023
Q2 		$512K Buy
+30,031
New +$449K ﹤0.01% 610

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

ALPS Advisors's MLYS Position: Q1 2026 in Review

ALPS Advisors reduced its Mineralys Therapeutics (MLYS) stake by 0.87% in Q1 2026, selling an estimated $16.7K and leaving 64,419 shares worth $1.75M. The position accounts for 0.01% of the portfolio, ranked #432.

ALPS Advisors first reported a position in MLYS in Q2 2023 and has held it in 10 quarters since. The position peaked at $2.36M in Q4 2025. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • ALPS Advisors held 64,419 shares of Mineralys Therapeutics worth $1.75M as of Q1 2026.
  • ALPS Advisors sold 568 Mineralys Therapeutics shares in Q1 2026, an estimated $16.7K.
  • Mineralys Therapeutics made up 0.01% of ALPS Advisors's portfolio in Q1 2026, its #432 holding.
  • ALPS Advisors first reported a position in Mineralys Therapeutics in Q2 2023 and has held it in 10 quarters since.
  • ALPS Advisors's Mineralys Therapeutics position peaked at $2.36M in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on ALPS Advisors's 13F filing for Q1 2026, filed 8 May 2026.